Navigation Links
Hologic to Participate in Three Investor Conferences
Date:11/10/2010

BEDFORD, Mass., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that company management will participate in the following conferences:

  • Rob Cascella, President and Chief Executive Officer, will present at the J.P. Morgan SMid Conference in New York City on Thursday, December 2, 2010, at 4:30 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at www.hologic.com/investors-overview. An archive of the presentation will be available for replay following the conference.
  • Glenn Muir, Executive Vice President and Chief Financial Officer, will host investor meetings at the Lazard Capital Markets Medical Technology Corporate Access Day in Denver on Thursday, December 2, 2010. Management will not be presenting at this conference and therefore there will be no webcast.
  • Deborah Gordon, Vice President of Investor Relations, will host investor meetings at the Nasdaq OMX 25th Investor Program in London on Tuesday, December 7, 2010. Management will not be presenting at this conference and therefore there will be no webcast.

  • About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact:

    Deborah GordonVice President, Investor RelationsHologic, Inc.(781) 999-7716
    '/>"/>

    SOURCE Hologic, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
    2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
    3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
    4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
    5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
    6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
    7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
    8. Hologic Expands Healthcare Investment in Asia
    9. Hologic to Host Investor Reception at RSNA 2009
    10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
    11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2016)... -- According to the 2016 report, a ... blood pressure monitoring system market growth. With aging, the ... respond to different pressure rates, leading to hypertension or ... cardiovascular disorders such as heart failure, stroke, coronary artery ... in prevalence each year. WHO estimates that 17 million ...
    (Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
    (Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
    Breaking Medicine Technology:
    (Date:5/27/2016)... ... 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield of ... 2016 honorees. The award recognizes businesswomen who excel in their fields and who ... the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa ...
    (Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., the maker ... been recognized as one of the best small businesses for new dads by Fatherly, ... nine small businesses providing progressive benefits to new parents on the organization’s 2016 ...
    (Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses ... time to shed lights on the variety of topics detailing why we appreciate nurses ... tackles why this career has gone from being in a major recession to one ...
    (Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... needing intervention to walk, the demand for a sustainable product to aid in the ... void and aid in the recovery of individuals with hemiplegia due to stroke. , ...
    (Date:5/27/2016)... ... ... This campaign aims to provide a path to improved education and awareness ... change. , As nearly 795,000 Americans suffering from a new or recurrent stoke each ... an estimated 129,000 of these people dying from stroke, it’s become our nation’s fifth-leading ...
    Breaking Medicine News(10 mins):